In addition, MedMira has recently shipped several follow-on orders to existing European distributors in Germany and The Netherlands. MiraCare HIV is MedMira’s CE-Marked rapid HIV test approved for use with whole blood, as well as serum and plasma specimens.
Hermes Chan, president and CEO of MedMira, said: “The increasing sales activity in Europe indicates that our test is gaining a strong foothold in the marketplace; a direct result of the targeted efforts put forth by our sales and marketing team to build a quality, high-performance distribution network for this region. The quality, speed and accuracy of the MiraCare HIV test is second to none, and we intend to continue our focus on building towards sustainable sales in this marketplace.”